CLINICAL TRIALS

Paradigm is in planning for its next phase of clinical trials, but is not currently recruiting. 

All information regarding future recruitment activity will be published via our ASX announcements, on our website, and via an appropriate clinical trial registry.

Phase 2 clinical trial for patients with BMLs and Osteoarthritis

A phase 2b, randomised double blind placebo controlled multicentre study to evaluate the effects of pentosan polysulfate sodium on treating pain in subjects with osteoarthritis of the knee and subchondral bone marrow lesions. Details can be found on the ANZCTR website here.

18 December 2018

Paradigm Biopharmaceuticals Ltd announced that it had met its primary endpoint in its phase 2b randomised double-blind placebo-controlled multi-centre clinical trial. Please see our ASX announcements and the video below for more information.

Ross River Virus (RRV)

A pilot study to investigate the effects of pentosan polysulfate sodium in Ross River.

Details can be found on the ANZCTR website here.

4 June 2019

Paradigm Biopharmaceuticals Ltd is pleased to report on its successful Ross River Phase 2A clinical trial. Further details can be found in our ASX announcement.